03 · What You Need to Know
How New Evidence Can Change an Approved Study
The Original Risk-Benefit Assessment Is Not Permanent
An ethics committee approves research based on the information reasonably available at that time. That includes what is known about anticipated harms, potential benefits, safeguards, alternatives, participant characteristics, and the value of the knowledge expected from the study.
Those facts can change.
The 2024 Declaration of Helsinki requires research risks and burdens to be continuously monitored, assessed, and documented. When risks and burdens are found to outweigh potential benefits, researchers must assess whether to continue, modify, or immediately stop the research.
The implication is straightforward: ethical acceptability is a continuing condition, not a historical fact established on the date of approval.
Not Every New Finding Materially Changes the Balance
A participant may experience an expected mild adverse effect at approximately the anticipated frequency. A new publication may confirm what researchers already knew. An interim analysis may remain compatible with the assumptions used when the protocol was approved.
Those developments may still require documentation or reporting under the applicable framework, but they do not necessarily alter the ethical balance.
The more important question is whether the new evidence changes something that mattered to the original justification.
New Information Can Increase the Probability of Harm
Suppose a complication was originally estimated to occur rarely, but accumulating data show that it is substantially more frequent.
The nature of the harm has not changed. The probability has.
OHRP's guidance on unanticipated problems specifically recognizes events that are unexpected in frequency and information suggesting that research places participants at greater risk than previously known or recognized. Such information may warrant substantive protocol changes, additional monitoring, suspension of enrollment, modification of consent information, or other corrective action.
A risk that was originally acceptable partly because it was thought to be very uncommon may therefore require a different judgment when that assumption no longer holds.
New Information Can Increase the Magnitude of Harm
A known category of adverse effect may also turn out to be more serious than anticipated.
For example, researchers may have expected a temporary and reversible reaction but later discover that some cases can produce persistent impairment. Even if the event's frequency remains unchanged, its ethical significance has increased because its consequences are now understood differently.
This is why probability and magnitude should remain separate in ongoing risk assessment. A changed estimate of either may alter the balance.
A Previously Unknown Type of Harm Can Appear
Sometimes new evidence identifies an entirely different pathway to harm.
A behavioral intervention may unexpectedly create social consequences. A digital study may reveal a re-identification vulnerability. A biological intervention may produce an adverse effect not predicted by earlier evidence.
Under OHRP's framework, an incident can constitute an unanticipated problem when it is unexpected, related or possibly related to participation, and suggests greater risk than previously recognized. Importantly, an unanticipated problem does not always require that someone has already suffered detectable harm.
Benefits Can Change Too
Ongoing ethical assessment should not focus exclusively on new harms.
An intervention may prove more beneficial than expected. Conversely, interim evidence may suggest that the anticipated benefit is smaller than researchers originally believed. A new external study may show that the experimental approach is ineffective or that another treatment performs substantially better.
If the benefit side weakens while risk remains constant, the risk-benefit balance can deteriorate without any new adverse event occurring.
Risk increases
The probability, magnitude, duration, or range of possible harms becomes greater than previously understood.
Benefit decreases
The prospect, magnitude, or relevance of anticipated participant benefit becomes smaller than previously expected.
Knowledge value decreases
Continuing the study becomes less scientifically necessary or informative because the question has already been answered or the design can no longer answer it adequately.
Any of these changes can affect the ethical justification even though they arise through different mechanisms.
A New Effective Alternative Can Change the Balance
Risk-benefit assessment does not occur in an informational vacuum. What participants could receive outside the research may matter.
Suppose a study began when no effective treatment existed. During the study, strong evidence establishes an effective standard treatment. Continuing to expose participants to a risky experimental intervention, placebo, delayed treatment, or another study condition may now require reconsideration even if nothing about the research procedure itself has changed.
The new information changes the alternatives available to participants and potentially changes what they give up or risk by remaining in the study.
New Evidence Can Reduce the Scientific Value of Continuing
A study can also become ethically less favorable because the knowledge it is expected to produce is no longer sufficiently valuable.
Suppose another large, rigorous study answers the same primary question conclusively while your trial is still enrolling. If continuing your study is unlikely to add meaningful information, participants may continue bearing research risks and burdens for diminishing scientific value.
The Declaration of Helsinki states that when there is conclusive proof of definitive outcomes, researchers must assess whether to continue, modify, or immediately stop the research.
Ethical reassessment therefore concerns information value as well as safety.
New Information Can Strengthen the Case for Continuing
Not every change moves toward stopping.
New evidence may show that an intervention is safer than expected, that safeguards are highly effective, or that the potential benefit is greater than originally anticipated. Such information can improve the risk-benefit profile.
Researchers should still interpret favorable findings cautiously, especially when interim data are incomplete. But ongoing ethical assessment should be capable of recognizing improvement as well as deterioration.
Changes in Uncertainty Can Matter Even Before the Best Estimate Changes
Imagine that researchers initially believed a serious adverse effect was extremely unlikely but had little evidence. New data reveal substantial uncertainty about that assumption without yet establishing a higher event rate.
The numerical estimate may not have formally changed, but confidence in it has.
That can matter ethically. A study whose justification depended heavily on a supposedly remote serious risk may require stronger safeguards or additional scrutiny when the evidence supporting that reassurance becomes less secure.
One Event May Be Enough, but Sometimes a Pattern Is Needed
A single unexpected catastrophic event plausibly related to research may immediately challenge the original assessment. A single mild event may not.
Conversely, repeated individually modest events may reveal a pattern showing that a procedure is more harmful or burdensome than expected.
OHRP guidance recognizes both severity and frequency when determining whether events suggest greater risk than previously known.
The relevant unit of analysis is therefore not automatically “one adverse event.” Researchers should interpret each signal in the context of accumulating evidence.
New Information From Outside Your Study Still Counts
Researchers should not wait for their own participants to experience a known problem before reconsidering the protocol.
Relevant information may come from another site, another trial, a published study, regulatory action, product safety information, a data monitoring committee, or other credible evidence. OHRP specifically notes that IRBs should consider whether new information from the research itself or other sources could alter previous determinations, particularly regarding participant risk.
The ethical question is what is now reasonably known, not where the knowledge originated.
The New Information May Change What Participants Would Choose
A changed risk-benefit balance also has implications for informed consent.
Participants agreed based on a particular understanding of risks, potential benefits, and alternatives. Significant new information may make that understanding outdated even if the study remains ethically permissible.
SACHRP notes that informed consent is an ongoing process and that significant new information can include revised risk information or information arising from an unanticipated problem. Whether and how participants should receive it depends on the nature and urgency of the information and their status in the study.
Watch Out
Do not ask only whether the new information is serious enough to stop the study. It may be important enough to change monitoring, eligibility, consent, or participant choice even when the study can ethically continue.
Reassessment Does Not Automatically Mean Suspension
A materially changed risk-benefit balance calls for action, but the appropriate action depends on the problem.
Additional monitoring may adequately address one new risk. Another may require exclusion of participants with particular characteristics. A third may require revised consent information. Some signals justify temporarily suspending enrollment or procedures while evidence is evaluated. Others may make continued research untenable.
OHRP identifies this range of responses, including protocol modification, additional monitoring, suspension of new enrollment, suspension of procedures in current participants, revised consent, and provision of new risk information to enrolled participants.
The Question Is Whether the Original Ethical Reasons Still Hold
A practical way to reassess a study is to reconstruct the original justification.
Original risk
What probability and magnitude of harm were expected when the study was approved?
Original benefit
What participant benefits, if any, were reasonably anticipated?
Original knowledge value
What important uncertainty was the study expected to resolve?
Original alternatives
What options were available to participants outside the study?
New evidence
Which of those assumptions has changed enough that the previous conclusion may no longer follow?
This approach prevents every new fact from triggering a complete ethical reset while making it difficult to ignore information that undermines a premise on which approval depended.
